40 / 42
Iniciativas de armonización y estandarización de la TMB
Friends of Cancer Research
https://www.focr.org/tmbInternational Quality Network for Pathology
http://www.iqnpath.org/•
Participating organisations
1-3
:
–
Pharma:
undisclosed
–
Diagnostic companies:
Foundation Medicine,
Ilumina, NEO New Oncology, Qiagen, Thermo
Fisher Scientific
–
Others:
11 academic pathology institutes in
Germany and Switzerland
These initiatives collectively aim to better understand the parameters used for TMB assessment, establish standards, and
compare existing assays to understand how they relate to one another
•
Participating organizations
1,5,6
:
–
European Society for Medical Oncology (ESMO)
–
Others undisclosed
Quality Assurance Initiative Pathology
https://quip.eu/en_GB/•
Participating organisations
1,2,4
:
–
Pharma:
AstraZeneca, BMS,
EMD Serono, Genentech, MSD, Pfizer
–
Diagnostic companies:
ACT Genomics,
Foundation Medicine, Guardant Health,
Illumina, NeoGenomics, OmniSeq, PGDx,
Qiagen, Thermo Fisher Scientific
–
Others:
FDA, MSKCC, NCI
1.
https://www.focr.org/news/genomeweb-two-initiatives-seek-harmonize-tumor-mutational-burden-testing.Accessed July 31, 2018.
2. Stenzinger A et al. Poster presentation at ESMO 2018. Abstract 141P.
3.
https://quip.eu/en_GB/2018/05/14/tumor-mutational-burden-tmb-quip-organisiert-studie-und-arbeitet-mit-focr-zusammen/.Accessed July 31, 2018.
4.
https://www.focr.org/tmb.Accessed June 1, 2018.
5.
http://www.iqnpath.org/wp-content/uploads/2018/04/IQNPath_AnnualReport2017-26032018.pdf.Accessed July 31, 2018.
6.
http://thermofisher.mediaroom.com/2018-09-06-Thermo-Fisher-Scientific-to-Showcase-Latest-Advances-in-Tumor-Mutation-Burden-at-ECP.Accessed September 17, 2018.